小檗胺衍生物PA4治疗淋巴瘤的药理学特征研究
研究合成小檗胺衍生物PA4,比较其与BBM的效力和特异性,发现PA4对淋巴瘤和白血病细胞毒性更强,通过增加活性氧和影响c-Myc蛋白稳定性发挥作用,在T细胞淋巴瘤小鼠模型中抑制肿瘤生长,口服生物利用度为34.1%。
要点
- PA4较BBM效力和特异性提高,对淋巴瘤和白血病细胞毒性强于其他癌种。
- PA4细胞毒作用与增加活性氧产生及间接靶向c-Myc蛋白稳定性相关。
- PA4口服后5.33±2.31小时达峰浓度1680±479 ng/mL,绝对生物利用度34.1%。
核心结论
- 鉴于PA4的疗效、安全性和良好的药代动力学特征,PA4是治疗淋巴瘤的潜在先导候选化合物。
研究设计与样本
- 基于既往对小檗胺(BBM)作为CAMKIIγ抑制剂的研究,合成新的BBM衍生物PA4,并开展体外细胞毒实验、机制研究、体内异种移植T细胞淋巴瘤小鼠模型药效评价、药代动力学研究和毒性评估。
主要发现
- 与BBM相比,PA4显示出更高的效力和特异性,对淋巴瘤和白血病细胞的细胞毒性强于对其他类型癌症细胞。
- PA4的细胞毒作用除间接靶向c-Myc蛋白稳定性外,还通过增加淋巴瘤细胞中活性氧产生介导。
- PA4在异种移植T细胞淋巴瘤小鼠模型中显著抑制肿瘤生长。
- 口服给药后PA4快速吸收入血浆,达峰浓度为1680±479 ng/mL,达峰时间为5.33±2.31小时,计算的口服绝对生物利用度为34.1%。
- PA4的毒性评估显示实验所用治疗窗对未来开发是安全的。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ca2+/calmodulin-dependent protein kinase II γ (CAMKIIγ) has been identified as a potential target for treating cancer. Based on our previous study of berbamine (BBM) as a CAMKIIγ inhibitor, we have synthesized a new BBM derivative termed PA4. Compared with BBM, PA4 showed improved potency and specificity and was more cytotoxic against lymphoma and leukemia than against other types of cancer. In addition to indirectly targeting c-Myc protein stability, we demonstrated that its cytotoxic effects were also mediated via increased reactive oxygen species production in lymphoma cells. PA4 significantly impeded tumor growth in vivo in a xenograft T-cell lymphoma mouse model. Pharmacokinetics studies demonstrated quick absorption into plasma after oral administration, with a maximum concentration of 1680 ± 479 ng/mL at 5.33 ± 2.31 hours. The calculated oral absolute bioavailability was 34.1%. Toxicity assessment of PA4 showed that the therapeutic window used in our experiments was safe for future development. Given its efficacy, safety, and favorable pharmacokinetic profile, PA4 is a potential lead candidate for treating lymphoma.
引用
- Xu S, Wu S, Zhang M, et al. Pharmacological profiling of a berbamine derivative for lymphoma treatment. Blood Adv. 2024. PMID: 37967356. doi:10.1182/bloodadvances.2023010873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。